Ethical Publishing Policy

Ethical Publishing Practice

MedPharmRes follows the best practice in publication ethics and expects that authors comply with its policy. The journal does not allow any forms of plagiarism, manipulation of figures, competing interests, dual submission, or inappropriate authorship (for example, ghost or guest authorship should be avoided).

Reviewers and editors are expected to declare any competing interests and treat all manuscripts fairly and confidentially. Any allegations of research or publication misconduct will be seriously investigated. MedPharmRes will treat suspected or alleged misconduct according to its established protocol. Any conclusive evidence of misconduct will change the manuscript’s scientific records, which may include issuing a correction or retraction. MedPharmRes reserves the right to contact authors’ institutions, funding agencies or regulatory bodies if needed to investigate suspected or alleged cases of publication misconduct.

Any concerns about potential misconduct should be directed via email to the Journal’s Editor-in-Chief (link to email address) or Journal’s Editorial Staff (link to email) and should not be communicated on blogs, other means of social media or other third party websites.

Plagiarism

MedPharmRes does not accept plagiarism at any form and will treat plagiarism according to the COPE guidelines. If plagiarism is detected during the peer review process, the manuscript may be rejected. If plagiarism is detected after publication, we may issue a correction or retraction of the paper. We reserve the right to inform authors' institutions on plagiarism detected either before or after publication

  • Editors and reviewers are expected to strictly evaluate submitted manuscripts and notify the journal of any plagiarism detected or suspected.
  • Plagiarism includes, but is not limited to:
    • Directly copying text from other sources without attribution
    • Copying ideas, images, or data from other sources without attribution
    • Reusing text from your own previous publications without attribution or agreement of the editor (read the MedPharmRes guidelines on text recycling http://medpharmres.com/ethical-publishing-policy)
    • Exception: Reusing text from the Methods section in the author’s previous publications, with attribution to the source, is acceptable.
    • Using an idea from another source with slightly modified language without attribution

Confidentiality

MedPharmRes respects the integrity of the peer-review process and strictly ensures the confidentiality of all submitted materials until published. The confidentiality must be ensured by all parties including editors, reviewers and authors during the peer-review process and all correspondences. Information on submission must not be shared with any other unrelated parties unless previous agreements made between all related parties. The involvement of a third party in the review must be declared at the time of the review submission.

Editors and reviewers are expected not to make use of any materials or take advantage of any information they gain through the peer review process. MedPharmRes will detect and seriously handle all breaches of confidentiality. Any concerns on confidentiality misconduct that arise during the review process will be strictly investigated according to COPE guidelines.

Submission and Publication of Related Studies

Author requirements

Authors must indicate at the time of submission whether their submitted manuscripts or any materials of their submitted manuscripts have been submitted or published elsewhere. Authors must include copies of previously published or submitted manuscripts and describe its relationship to their current submitted manuscript.

Prior publication of research as a thesis, presentation at medical or scientific conferences, or posting on preprint servers will not preclude consideration of your manuscript.

MedPharmRes supports the public disclosure of all clinical trial results, as mandated. Prior disclosure of results on a clinical trial registry site will not affect consideration.

Editor and reviewer requirements

Reviewers and editors are expected to evaluate any related materials and notify the overlap and alert duplicated submission or publication during the review process to MedPharmRes.

Policy enforcement

A manuscript will be rejected if it is deemed to share substantial similarity to or be a duplicate of previous submission at MedPharmRes. If duplicate content is discovered after publication, correction or retraction will be applied as appropriate.

Figure Preparation

Image files should not be manipulated or adjusted in any way that could lead to misinterpretation of the information presented in the original image. Read more about our guidelines on reporting blots and gel data and uploading original image files and on Preparing Figures from Image Files.

Biosecurity and Dual Use Research of Concern

We recognize that certain research may fall into the category of “dual use research of concern.” This is defined by the National Science Advisory Board for Biosecurity (NSABB) of the United States National Institutes of Health as any "biological research with legitimate scientific purpose that may be misused to pose a biologic threat to public health and/or national security."

MedPharmRes Editorial Boards and Staff are committed to the widespread dissemination of research while being sensitive to the issues of responsible publication standards. In this context, we assess the risks and benefits of publishing the research. If the risks outweigh the benefits, we will not publish it.

Author requirements

Authors must disclose potential bioethics /dual use concerns to the journal office at the time of initial submission.

Editor and reviewer requirements

Editors and reviewers are expected to vigilantly evaluate all potential risks and alert any concerns to MedPharmRes.

Policy enforcement

We follow the standards set by the University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam. Each manuscript is checked at the submission for any potential risk of policy violation. Immediate rejection after submission receipt may be applied to manuscripts with identified risks. If risks are identified after a paper published, MedPharmRes will minimize the risk according to the prevailing guidelines and may contact authors’ institution for considering a fine.